NCT01862939View on ClinicalTrials.gov

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

DS-7309

1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.

DRUG

placebo

placebo to match part 2 DS-7309

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT01862939 - A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter